Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML)

Autoria(s): O'Dwyer, M.E.; Swords, R.; Giles, F.; McMullin, Mary Frances; Le Coutre, P.D.; Nagler, A.; Langabeer, S.; Wieczorkowska, M.; McDowell, C.; Egan, K.; Moulton, B.; Conneally, E.
Data(s)

01/12/2011
Identificador

http://pure.qub.ac.uk/portal/en/publications/analysis-of-the-genexpert-system-on-the-international-multicentre-icorg-0802-phase-ii-study-of-nilotinib-300mg-bid-as-frontline-treatment-in-patients-with-early-chronic-phase-chronic-myeloid-leukemia-ecpcml(b2acf3ee-2e24-45c0-a437-b37c0b8843b5).html
Idioma(s)

eng
Direitos

info:eu-repo/semantics/restrictedAccess
Fonte

O'Dwyer , M E , Swords , R , Giles , F , McMullin , M F , Le Coutre , P D , Nagler , A , Langabeer , S , Wieczorkowska , M , McDowell , C , Egan , K , Moulton , B & Conneally , E 2011 , ' Analysis of the GeneXpert System on the International Multicentre ICORG 08-02 Phase II Study of Nilotinib 300mg BID as Frontline Treatment in Patients with Early Chronic Phase Chronic Myeloid Leukemia (ECPCML) ' Blood , vol 118 , pp. 1612-1613 .
Tipo

article
Acesso ao item digital